iShares U.S. Healthcare ETF News - August 2026
Eli Lilly’s Mounjaro wins FDA heart approval, boosting blockbuster market lead
The FDA approved an expanded indication for Eli Lilly’s Mounjaro to reduce the risk of major adverse cardiovascular events (MACE). This approval applies to...
Revolution Medicines wins FDA approval, doubling survival in pancreatic cancer patients
The U.S. Food and Drug Administration granted expedited approval to Revolution Medicines' new drug, daraxonrasib (brand name: Rasonque). This first-of-its-kind...
Quest Diagnostics to Offer First FDA-Cleared Alzheimer's Blood Test, Replacing Invasive Scans
Quest Diagnostics will begin offering Roche's Elecsys Phospho-Tau (217P) Plasma (pTau217) assay. This is the first and only FDA-cleared blood test designed to...
Trump Nominates Dr. Heidi Overton for FDA, Signaling Vaccine Policy Shift
President Donald Trump nominated Dr. Heidi Overton to lead the Food and Drug Administration. Dr. Overton currently serves as a White House health policy aide...
Moderna, Merck shares surge on successful Phase 3 cancer vaccine trial
Merck and Moderna announced that their individualized neoantigen therapy, intismeran, met its primary endpoint in a Phase 3 melanoma trial. The combination of...
Bristol-Myers Squibb Wins FDA Approval for Iberdomide, Using Landmark Cancer Endpoint
The FDA approved Bristol-Myers Squibb’s iberdomide combination therapy for adults with relapsed or refractory multiple myeloma. This regimen combines...
Replimune Gains FDA Approval for TUDRIQEV, Transitioning to Commercial Stage
The FDA granted Replimune Group Inc. accelerated approval for its oncolytic immunotherapy, TUDRIQEV. The drug treats patients with advanced cutaneous melanoma...
AstraZeneca eyes Bristol Myers merger, creating $400B oncology powerhouse
AstraZeneca is discussing a merger with U.S. rival Bristol Myers Squibb. The potential deal would value the combined pharmaceutical giant at nearly $400...
AstraZeneca eyes $400B Bristol Myers Squibb merger, targeting oncology dominance
Britain's AstraZeneca is reportedly discussing a merger with U.S. rival Bristol Myers Squibb. The potential deal values the combined company at nearly $400...
AstraZeneca and Bristol Myers Squibb in Talks for Potential $400B Mega-Merger
Britain's AstraZeneca is reportedly in discussions to merge with U.S. rival Bristol Myers Squibb in a deal that would create a pharmaceutical giant valued at...
J&J secures $2.58B option for Sail Biomedicines, targeting in-body cell therapy
Johnson & Johnson secured an option to acquire Sail Biomedicines for up to $2.58 billion. This investment targets Sail’s novel in vivo chimeric antigen...